

Literaturverzeichnis

1. Boveri TH:
Zur Frage der Entstehung maligner Tumoreen
Jena, Verlag von Gustav Fischer, 1914, S.22

2. Linnemann M, Kühl M:
Biochemie für Mediziner
Wiesbaden, Verlag Vieweg, 1995, S.452-453

3. Passarge E:
Taschenatlas der Genetik
Thieme Verlag, 1994, S.260-275

4. Burck KB, Liu ET, Larrick JW:
Oncogenes, An introduction to the concept of Cancer Genes
Springer Verlag, 1988, S.101-133

5. Knudson AG:
Mutation and Cancer: Statistical Study of Retinoblastoma
Proc. Nat. Acad. Sci. USA 68: 820-823, 1971

6. Li FP, Fraumeni JF:
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
An. of Int. Med. 71: 747-752, 1969

7. Malkin D, Li FP, Strong LC, Fraumeni JF u.a.:
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas,
and Other Neoplasms
Science 250: 1233-1238, 1990

8. Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y u. a.:
Homozygous Deletion and Frequent Allelic Loss of Chromosome 8p22 Loci in Human Prostate Cancer
Canc. Res. 53: 3869-3873, 1993
9. Takhashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG u.a.:
Frequent Loss of Heterozygosity at 7q31.1 in Primary Prostate Cancer Is Associated with Tumor Aggressiveness and Progression
Canc. Res. 55: 4114-4119, 1995
10. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS u.a.:
An Uncertain Role for p53 Gene Alterations in Human Prostate Cancer
Canc. Res. 56: 3814-3822, 1996
11. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ:
Identification and Characterization of Proximal 6q Deletions in Prostate Cancer
Canc. Res. 56: 4150-4153, 1996
12. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB u.a.:
Down-Regulation of the KAI1 Metastasis Suppressor Gene during the Progression of Human Prostate Cancer Infrequently Involves Gene Mutation or Allelic Loss
Canc. Res. 56: 4387-4390, 1996
13. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ:
Distinct Regions of Allelic Loss on 13q in Prostate Cancer
Canc. Res. 56: 1142-1145, 1996
14. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE u.a.:
Analysis of 99 Microdissected Prostate Carcinomas Reveals a High Frequency of Allelic Loss on Chromosome 8p12-21
Canc. Res. 56: 2411-2416, 1996

15. Grönberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS u.a.:
Early Age at Diagnosis in Families Providing Evidence of Linkage to the
Hereditary Prostate Cancer Locus (HPC1) on Chromosome 1
Canc. Res. 57: 4707-4709, 1997
16. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R:
Loss of Heterozygosity at Chromosome 16q in Prostate Adenocarcinoma:
Identification of Three Independent Regions
Canc. Res. 57: 1058-1062, 1997
17. Gray IC, Phillips SMA, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK:
Loss of the Chromosomal Region 10q23-25 in Prostate Cancer
Canc. Res. 55: 4800-4803, 1995
18. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA:
Distinct Areas of Allelic Loss on Chromosomal Regions 10p and 10q in Human
Prostate Cancer
Canc. Res. 56: 2263-2267, 1996
19. Cairns P, Okami K, Halachmi S, Esteller M u.a.:
Frequent Inactivation of PTEN/MMAC1 in Primary Prostate Cancer
Canc. Res. 57: 4997-5000, 1997
20. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PLM u.a.:
Mutation spectrum and genotype-phenotype analyses in Cowden disease and
Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN
Mutation
Hum. Mol. Gen. 7: 507-515, 1998
21. Hopkins K:
A Surprising Function for the PTEN Tumor Suppressor
Science 282: 1027-1030, 1998

22.Maehama T, Dixon JE:

PTEN: a tumor suppressor that functions as a phospholipid phosphatase
Cell Biol. 9: 125-128, 1999

23.Blümcke S:

Pathologie
Walter de Gruyter Verlag, Berlin 1995, S.730-735

24.Noltenius:

Tumor Handbuch Band 4
Urban und Schwarzenberg Verlag, München 1987, S.1537-1546

25.Mertin A:

Neue Therapie bei Brustkrebs
Die Welt vom 12.03.1999, Frankfurt/Main

26.Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H u.a.:

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome
10q23.3 that is mutated in multiple advanced cancers
Nat. Gen. 15: 356-362, 1997

27.Invitrogen Corporation:

Instruction Manual TOPO™ TA Cloning, Version E
Carlsbad, CA 92008, 1600 Faraday Avenue, 1997

28.Human genetic linkage map

Nat. 380: 152-154, A68-A73, 1996

29.Boström J, Cobbers JM JL, Wolter M, Tabatabai G u.a.:

Mutation of the PTEN (MMAC1) Tumor Suppressor Gene in a Subset of
Glioblastomas but not in Meningiomas with Loss of Chromosome Arm 10q
Canc. Res. 58: 29-33, 1998

30. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R:
Somatic Mutations of PTEN in Glioblastoma Multiforme
Canc. Res. 57: 4183-4186, 1997
31. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G u.a.:
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Oncog. 16: 2879-2883, 1998
32. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C u.a.:
PTEN/MMAC1 is frequently mutated in pT2 and pT3 carcinomas of the prostate
Oncog. 17: 1979-1982, 1998
33. Orikasa K, Fukushige S, Hoshi S, Orikasa u.a.:
Infrequent genetic alterations of the PTEN gene in Japanese patients with
sporadic prostate cancer
J Hum. Genet. 43: 228-230, 1998
34. Rubin MA, Gerstein A, Reid K, Bostwick DG u.a.:
10q23.3 Loss of Heterozygosity is higher in Lymph Node-Positive (pT2-3,N+)
Versus Lymph Node-Negative (pT2-3,NO) Prostate Cancer
Hum. Path. 31: 504-508, 2000
35. Fearon ER, Vogelstein B:
A Genetic Model for Colorectal Tumorigenesis
Cell 61: 759-767, 1990